Sun Pharma Q4 Results 2022

Pharmaceutical giant Sun Pharma posted its Q4 FY22 results on May 30, 2022. 

The company reported a surprise loss of Rs 2,277 crore in the quarter under review from a net profit of Rs 2,058 crore in the previous quarter and a net profit of Rs 894 crore last year.

The surprising loss in Q4 FY22 was attributed largely to a one-time charge of the antitrust payment and other lawsuit settlements made in the U.S related to its subsidiary Taro Pharmaceuticals. This cost the company a whopping Rs 3,723 crore in lawsuit settlements. In addition to this, Sun Pharma also made an expenditure of Rs 56.35 crore to restructure its operations in certain countries.

The company’s revenue from operations was down by 4.2% QoQ (Quarter on Quarter) to Rs 9,446 crore in the quarter under review from Rs 9,863 crore in the previous quarter. On a YoY (Year on Year) basis, the revenue from operations was up 10.8%.

Sun Pharma’s Board of Directors recommended a final dividend of Rs 3 per equity share, subject to the shareholders’ approval.

Highlights of Sun Pharma Q4 Results 2022

• Revenue from operations was up 10.8% YoY to Rs 9,446 crore in Q4 FY22 
• Total income up 10.7% YoY to Rs 9,560 crore in the quarter under review
• U.S sales, which accounted for 31% of the total sales, rose 5% on a yearly basis 
• India sales up 16% to Rs 3,095 crore
• Sales in emerging markets up 7% to $206 million
• EBITDA for the quarter rose 15% to Rs 2,279 crore

Misses of Sun Pharma Quarterly Results

• The company reported a net loss of Rs 2,277 crore in the quarter under review from a profit of last year same period
• Revenue from operations was down by 4.2% QoQ which came in at Rs 9,446 crore in Q4FY22
• Total income down by 7.1% QoQ to Rs 9,560 crore in Q4FY22
• Earnings Per Share (EPS) was down to Rs -9.5 in the quarter under review against an EPS of Rs 8.6 in the previous quarter. And Rs 3.7 last year.

What the Management says

Dilip Shanghvi, Managing Director, Sun Pharmaceuticals said, that FY22 was a good year with strong topline and EBITDA growth. All geographies have recorded double-digit growth and profitability has improved despite rising costs. The specialty business continues to ramp up strongly with global Ilumya sales recording 81% growth to reach US$315 million in FY22.

Other things to know about Sun Pharma Results 2022

• The company re-appointed Dilip Sanghvi as the company’s Managing Director and Gautam Doshi as the Independent Director for a period of 5 years.
• Sun Pharma’s P/E ratio is at 74.69 against the industry average of 30.96
• The company’s P/B ratio is at 4.38 against the industry average of 4.73
• Sun Pharma’s dividend yield is at 0.83% against the industry average of 0.89%

To read the RA disclaimer, please click here
Research Analyst: Bavadharini KS